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AAS

:   androgenic anabolic steroid

ALP

:   alkaline phosphatase

ALT

:   alanine aminotransferase

AST

:   aspartate aminotransferase

GGT

:   gamma‐glutamyl transpeptidase

SARM

:   selective adrenergic receptor modulator

Traditional androgenic anabolic steroids (AASs), like testosterone, have positive anabolic (bone, muscle) actions, but androgenic (virilization, acne) effects limit their use. Selective androgenic receptor modulators (SARMs), such as Ligandrol, enobosarm, and RAD‐140, bind androgen receptors with tissue‐selective activity that promotes anabolic actions without significant androgenic effects. Although not U.S. Food and Drug Administration approved, they are heavily promoted as AAS alternatives and are being trialed in aging and muscle‐wasting disorders. Unlike AASs, which have well‐recognized hepatotoxic potential, only limited human hepatic safety data are available for SARMs.[1](#hep41456-bib-0001){ref-type="ref"}, [2](#hep41456-bib-0002){ref-type="ref"}, [3](#hep41456-bib-0003){ref-type="ref"}, [4](#hep41456-bib-0004){ref-type="ref"}

Patients and Methods {#hep41456-sec-0002}
====================

Case 1 {#hep41456-sec-0003}
------

A previously healthy 24‐year‐old man presented with a 5‐week history of jaundice, anorexia, nausea, lethargy, and weight loss of 5 kg. He had used a gym supplement (LGD‐4033 LIGANDROL capsules) for 9 weeks, and his symptoms developed a week after its cessation. He had a history of binge drinking once a month. He was not on any regular medications and gave no previous history of liver disease.

Examination revealed normal vital signs, jaundice, and mild hepatomegaly, without peripheral stigmata of chronic liver disease. His liver tests showed the following: bilirubin, 116 μmol/L (reference, \<30); alanine aminotransferase (ALT), 273 U/L (reference, \<45); aspartate aminotransferase (AST), 111 U/L (reference, \<45); alkaline phosphatase (ALP), 289 U/L (reference, \<100); gamma‐glutamyl transpeptidase (GGT), 62 U/L (reference \<110); platelets, 387 × 10^9^/L (reference, 150‐450); international normalized ratio (INR), 1.0; globulin, 34 g/L; creatinine, 114 (reference, \<110 μmol/L); eosinophil count, 0.21 × 10^9^/L (reference, 0.00‐0.70); and R ratio of 8.22 (indicating hepatocellular liver injury). Viral, autoimmune and metabolic liver diseases, and biliary obstruction were excluded by blood tests and liver ultrasonography.

The subject's bilirubin peaked at 116 μmol/L after 2 weeks, but his liver tests and creatinine normalized over 4 months (Table [1](#hep41456-tbl-0001){ref-type="table"}). Rechallenge was not performed.

###### 

Trend of Available Liver Tests Related to Nonsteroidal SARM Use for Case 1

  Case 1                                                   
  -------------------------------- ----- ----- ----- ----- ------------------------------------------------------------------
  Baseline                         29    ---   111   4     4 years prior
  −6 weeks                                                 SARM use ceased after 9 weeks of use
  −2 weeks                         589   175   197   68    Symptoms present for 3 weeks when seen by primary care physician
  −1 week                          273   111   289   116   Referred to hepatologist
  Initial review by hepatologist   160   76    272   92    
  2 weeks                          334   155   266   46    
  4 weeks                          178   ---   182   23    
  8 weeks                          79    ---   134   18    
  8 months                         20    ---   96    13    
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Case 2 {#hep41456-sec-0004}
------

A 49‐year‐old man presented with jaundice and itching of 5 weeks duration. His only regular medication was an antidepressant (venlafaxine) for 11 months. Four months prior to presentation, he reported using a SARM (RAD‐140) for 4 weeks and intermittent use thereafter. Investigations showed the following: bilirubin, 291 umol/L; ALT, 54 U/L; AST, 59 U/L; ALP, 327 U/L; GGT, 60 U/L; albumin, 40 g/L; globulin, 28 g/L; creatinine, 120 μmol/L (peaking at 132 μmol/L); INR, 1.2; platelets, 347 × 10^9^/L; and R ratio of 5.0 (indicating mixed hepatocellular--cholestatic liver injury). Alcohol consumption was insignificant. Appropriate blood tests and liver imaging excluded other liver diseases and biliary obstruction. Liver histology showed moderate cholestasis with ductopenia and minimal fibrosis and inflammation, consistent with drug‐induced liver injury. Venlafaxine was ceased, and he was treated with ursodiol and cholestyramine. His bilirubin peaked at 346 μmol/L but gradually improved over 2 months; all his liver tests and creatinine were completely normal when rechecked 12 months after his initial presentation (Table [2](#hep41456-tbl-0002){ref-type="table"}). Rechallenge was not performed.

###### 

Trend of Available Liver Tests Related to Nonsteroidal SARM Use for Case 2

  Case 2                                                   
  -------------------------------- ----- ----- ----- ----- ---------------------------------------------------------------------------------------------------------------------------------
  Baseline                         24    21    57    10    8 months prior
  −2 weeks                         200   111   111   80    Ordered by primary care physician for pruritus; referred to hepatologist; SARM use had ceased after intermittent use for months
  Initial review by hepatologist   54    63    327   291   
  2 weeks                          51    ---   299   321   
  3 weeks                          44    61    286   346   
  4 weeks                          60    65    262   187   
  8 weeks                          172   123   121   32    
  12 months                        27    ---   59    7     
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Results {#hep41456-sec-0005}
=======

In both cases, the supplements were sent for toxicologic analysis and were screened by ultra‐high performance liquid chromatography/photodiode array and gas chromatography--mass spectrometry. The presence of SARM in both cases (Ligandrol in case 1 and RAD‐140 in case 2) was confirmed, and no other contaminants were identified.

Discussion {#hep41456-sec-0006}
==========

To our knowledge, these individuals represent the first cases of significant liver injury with SARM. Mild, transient, self‐limiting increases in aminotransferases were reported in clinical trials,[1](#hep41456-bib-0001){ref-type="ref"}, [2](#hep41456-bib-0002){ref-type="ref"}, [3](#hep41456-bib-0003){ref-type="ref"}, [4](#hep41456-bib-0004){ref-type="ref"} but discontinuation due to raised ALT was rare (one case), and serious liver injury was not documented. Causality assessment scores (Roussel Uclaf Causality Assessment Method) for cases 1 and 2 were 7 and 6 points (probable), respectively.[5](#hep41456-bib-0005){ref-type="ref"} The Drug Induced Liver Injury Network (DILIN) causality score was 2 (probable) for both cases, and the DILIN severity score was 2 (moderate liver injury, case 1) and 3 (moderate to severe liver injury, case 2).[6](#hep41456-bib-0006){ref-type="ref"} In both cases, the presence of SARM in the supplements was confirmed and other contaminants (especially AASs) were excluded. In the first case, alcohol was a potential confounding factor, but the pattern of liver tests (ALT\>AST, normal GGT) was inconsistent with alcoholic hepatitis. In the second case, it is possible that venlafaxine may have contributed; however, he had been taking this for nearly a year, whereas venlafaxine hepatotoxicity is usually seen within 1 to 3 months (<https://livertox.nih.gov>).

The liver injury in both cases is within the described spectrum of liver injury associated with AASs. While case 2 showed the more well‐known cholestatic injury profile, the hepatocellular presentation of case 1 is also well described. These off‐target effects question the so‐called tissue selectivity of SARMs, which has been their main selling point.

Whether these cases represent the "tip of the iceberg" remains to be seen, but given the increasing popularity of SARM use, greater vigilance and reporting of potential cases is required.
